Genetic and epigenetic factors determining NAFLD risk
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Hepatic steatosis is a common chronic liver disease that can progress into more severe stages of NAFLD or promote the development of life-threatening secondary diseases for some of those affected. These include the liver itself (nonalcoholic steatohepatitis or NASH; fibrosis and cirrhosis, and hepatocellular carcinoma) or other organs such as the vessels and the heart (cardiovascular disease) or the islets of Langerhans (type 2 diabetes). In addition to elevated caloric intake and a sedentary lifestyle, genetic and epigenetic predisposition contribute to the development of NAFLD and the secondary diseases. SCOPE OF REVIEW: We present data from genome-wide association studies (GWAS) and functional studies in rodents which describe polymorphisms identified in genes relevant for the disease as well as changes caused by altered DNA methylation and gene regulation via specific miRNAs. The review also provides information on the current status of the use of genetic and epigenetic factors as risk markers. MAJOR CONCLUSION: With our overview we provide an insight into the genetic and epigenetic landscape of NAFLD and argue about the applicability of currently defined risk scores for risk stratification and conclude that further efforts are needed to make the scores more usable and meaningful.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tissue-based map of the human proteome
Uhlén, M., Fagerberg, L., Hallström, B. M., Lindskog, C., Oksvold, P., Mardinoglu, A., Sivertsson, Å., Kampf, C., Sjöstedt, E., Asplund, A., et al. (2015) · Science · doi:10.1126/science.1260419 · Cited by 15,286
EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
(2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.11.004 · Cited by 4,836
Mammalian microRNAs predominantly act to decrease target mRNA levels
Guo, H., Ingolia, N. T., Weissman, J. S., & Bartel, D. P. (2010) · Nature · doi:10.1038/nature09267 · Cited by 3,886 · cited 1×
“Each miRNA acts post-transcriptionally to control the expression of multiple genes by translational repression or interference with RNA stability [117,118].”
BackgroundPrevalence of Hepatic Steatosis in An Urban Population in the United States: Impact of Ethnicity
Browning, J. D., Szczepaniak, L. S., Dobbins, R., Nuremberg, P., Horton, J. D., Cohen, J. C., Grundy, S. M., & Hobbs, H. H. (2004) · Hepatology · doi:10.1002/hep.20466 · Cited by 3,664
Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease
Romeo, S., Kozlitina, J., Xing, C., Pertsemlidis, A., Cox, D., Pennacchio, L. A., Boerwinkle, E., Cohen, J. C., & Hobbs, H. H. (2008) · Nature Genetics · doi:10.1038/ng.257 · Cited by 3,416
Identification of tissue-specific microRNAs from mouse
Lagos-Quintana, M., Rauhut, R., Yalcin, A., Meyer, J., Lendeckel, W., & Tuschl, T. (2002) · Current Biology · doi:10.1016/s0960-9822(02)00809-6 · Cited by 3,355 · cited 1×
“MiR-122 stands out as it accounts for approximately 70% of all miRNAs expressed in the liver [121].”
BackgroundGenome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels
Saxena, R., Voight, B. F., Lyssenko, V., Burtt, N. P., de Bakker, P. I. W., Chen, H., Roix, J. J., Kathiresan, S., Hirschhorn, J. N., Daly, M. J., et al. (2007) · Science · doi:10.1126/science.1142358 · Cited by 2,843 · cited 6×
“In addition, association of rs780094 with other metabolic traits such as decreased fasting blood glucose [48] and decreased risk of T2D [49,50] were reported.”
BackgroundInfluentialA subcellular map of the human proteome
Thul, P. J., Åkesson, L., Wiking, M., Mahdessian, D., Geladaki, A., Ait Blal, H., Alm, T., Asplund, A., Björk, L., Breckels, L. M., et al. (2017) · Science · doi:10.1126/science.aal3321 · Cited by 2,813
Ahlqvist, E., Storm, P., Käräjämäki, A., Martinell, M., Dorkhan, M., Carlsson, A., Vikman, P., Prasad, R. B., Aly, D. M., Almgren, P., et al. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30051-2 · Cited by 2,335
miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting
Esau, C., Davis, S., Murray, S. F., Yu, X. X., Pandey, S. K., Pear, M., Watts, L., Booten, S. L., Graham, M., McKay, R., et al. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.005 · Cited by 2,082 · cited 2×
“They displayed reduced plasma cholesterol levels, increased hepatic fatty acid oxidation, and decreased rates of fatty acids and cholesterol synthesis in the liver [123].”
BackgroundKozlitina, J., Smagris, E., Stender, S., Nordestgaard, B. G., Zhou, H. H., Tybjærg-Hansen, A., Vogt, T. F., Hobbs, H. H., & Cohen, J. C. (2014) · Nature Genetics · doi:10.1038/ng.2901 · Cited by 1,234 · cited 2×
“PNPLA3 Liver and kidney Hepatocytes [43] Lipid droplet remodeling [40,42] Stellate cells [43] Modulation of retinol production and release [43,147] GCKR Liver, smooth muscle, and stomach Hepatocytes Increasing glycolytic flux [51], regulation of de novo lipogenesis [48,148] TM6SF2 RNA enriched in intestine and liver […”
BackgroundTilg, H., Moschen, A. R., & Roden, M. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.147 · Cited by 1,002
Speliotes, E. K., Yerges-Armstrong, L. M., Wu, J., Hernaez, R., Kim, L. J., Palmer, C. D., Gudnason, V., Eiriksdottir, G., Garcia, M. E., Launer, L. J., et al. (2011) · PLoS Genetics · doi:10.1371/journal.pgen.1001324 · Cited by 984
A Protein-Truncating HSD17B13 Variant and Protection from Chronic Liver Disease
Abul-Husn, N. S., Cheng, X., Li, A. H., Xin, Y., Schurmann, C., Stevis, P., Liu, Y., Kozlitina, J., Stender, S., Wood, G. C., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1712191 · Cited by 827 · cited 2×
“This effect was associated with a decrease in PNPLA3 mRNA in an allele dose-dependent manner [61].”
BackgroundInhibition of miR-33a/b in non-human primates raises plasma HDL and lowers VLDL triglycerides
Rayner, K. J., Esau, C. C., Hussain, F. N., McDaniel, A. L., Marshall, S. M., van Gils, J. M., Ray, T. D., Sheedy, F. J., Goedeke, L., Liu, X., et al. (2011) · Nature · doi:10.1038/nature10486 · Cited by 706
Liu, Y.-L., Reeves, H. L., Burt, A. D., Tiniakos, D., McPherson, S., Leathart, J. B. S., Allison, M. E. D., Alexander, G. J., Piguet, A.-C., Anty, R., et al. (2014) · Nature Communications · doi:10.1038/ncomms5309 · Cited by 623
Zaharia, O. P., Strassburger, K., Strom, A., Bönhof, G. J., Karusheva, Y., Antoniou, S., Bódis, K., Markgraf, D. F., Burkart, V., Müssig, K., et al. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30187-1 · Cited by 600 · cited 1×
“Based on several pathophysiological parameters, patients with adult-onset diabetes are allocated to five clusters [72,73].”
BackgroundBuch, S., Stickel, F., Trépo, E., Way, M., Herrmann, A., Nischalke, H. D., Brosch, M., Rosendahl, J., Berg, T., Ridinger, M., et al. (2015) · Nature Genetics · doi:10.1038/ng.3417 · Cited by 565 · cited 1×
“A genetic variant rs641738 (C > T) located near two genes encoding MBOAT7 and the transmembrane channel-like 4 (TMC4) was first reported to increase the risk of alcoholic cirrhosis [68], but a subsequent candidate gene study also linked rs641738 to NAFLD and disease progression [69].”
BackgroundPirola, C. J., Fernández Gianotti, T., Castaño, G. O., Mallardi, P., San Martino, J., Mora Gonzalez Lopez Ledesma, M., Flichman, D., Mirshahi, F., Sanyal, A. J., & Sookoian, S. (2015) · Gut · doi:10.1136/gutjnl-2014-306996 · Cited by 564 · cited 4×
“4-fold, respectively) between control and NASH [14].”
BackgroundInfluentialDongiovanni, P., Petta, S., Maglio, C., Fracanzani, A. L., Pipitone, R., Mozzi, E., Motta, B. M., Kaminska, D., Rametta, R., Grimaudo, S., et al. (2015) · Hepatology · doi:10.1002/hep.27490 · Cited by 533 · cited 1×
“In a human exome-wide association study [53], the rs58542926 (G> A; E167K) variant transmembrane 6 superfamily member 2 (TM6SF2) was associated with increased hepatic triglyceride content and higher risk of advanced fibrosis in NAFLD patients [53e55], but paradoxically associated with a lower concentration of hepatic-…”
BackgroundRich, N. E., Oji, S., Mufti, A. R., Browning, J. D., Parikh, N. D., Odewole, M., Mayo, H., & Singal, A. G. (2018) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2017.09.041 · Cited by 486 · cited 1×
“Therefore, the SNP rs738409 may partly explain the variable prevalence of hepatic steatosis among different ethnic groups in the US population [7], with individuals of Hispanic descent displaying more NAFLD (45%) than those of European descent (33%), who have a higher prevalence of NAFLD than those of African descent…”
BackgroundBeer, N. L., Tribble, N. D., McCulloch, L. J., Roos, C., Johnson, P. R. V., Orho-Melander, M., & Gloyn, A. L. (2009) · Human Molecular Genetics · doi:10.1093/hmg/ddp357 · Cited by 401 · cited 3×
“PNPLA3 Liver and kidney Hepatocytes [43] Lipid droplet remodeling [40,42] Stellate cells [43] Modulation of retinol production and release [43,147] GCKR Liver, smooth muscle, and stomach Hepatocytes Increasing glycolytic flux [51], regulation of de novo lipogenesis [48,148] TM6SF2 RNA enriched in intestine and liver […”
BackgroundRelationship Between Methylome and Transcriptome in Patients With Nonalcoholic Fatty Liver Disease
Murphy, S. K., Yang, H., Moylan, C. A., Pang, H., Dellinger, A., Abdelmalek, M. F., Garrett, M. E., Ashley–Koch, A., Suzuki, A., Tillmann, H. L., et al. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.07.047 · Cited by 391 · cited 2×
“suggested that the data might help to establish non-invasive markers to identify NAFLD patients at a high risk of liver disease progression [100].”
BackgroundMethodA feed-forward loop amplifies nutritional regulation of PNPLA3
Huang, Y., He, S., Li, J. Z., Seo, Y.-K., Osborne, T. F., Cohen, J. C., & Hobbs, H. H. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1003585107 · Cited by 386 · cited 2×
“High carbohydrate levels cause transcriptional upregulation of Pnpla3 and indirect inhibition of protein degradation [33], whereas Pnpla3 expression was reduced in mice by fasting [33,35].”
BackgroundHorie, T., Ono, K., Horiguchi, M., Nishi, H., Nakamura, T., Nagao, K., Kinoshita, M., Kuwabara, Y., Marusawa, H., Iwanaga, Y., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1008499107 · Cited by 384
Pnpla3I148M knockin mice accumulate PNPLA3 on lipid droplets and develop hepatic steatosis
Smagris, E., BasuRay, S., Li, J., Huang, Y., Lai, K. V., Gromada, J., Cohen, J. C., & Hobbs, H. H. (2015) · Hepatology · doi:10.1002/hep.27242 · Cited by 379
Mahdessian, H., Taxiarchis, A., Popov, S., Silveira, A., Franco-Cereceda, A., Hamsten, A., Eriksson, P., & van't Hooft, F. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1323785111 · Cited by 369
Pirola, C. J., Gianotti, T. F., Burgueño, A. L., Rey-Funes, M., Loidl, C. F., Mallardi, P., Martino, J. S., Castaño, G. O., & Sookoian, S. (2013) · Gut · doi:10.1136/gutjnl-2012-302962 · Cited by 364
Vitamin A signaling and homeostasis in obesity, diabetes, and metabolic disorders
Blaner, W. S. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.01.006 · Cited by 287 · cited 4×
“Based on several studies, a number of proteins involved in retinol metabolism, including retinol-binding protein 4 (RBP4) and aldehyde dehydrogenase 1A1 (ALDH1A1), have also been implicated in metabolic diseases including NAFLD and NASH [66].”
BackgroundInfluentialPNPLA3 I148M polymorphism and progressive liver disease
Dongiovanni, P. (2013) · World Journal of Gastroenterology · doi:10.3748/wjg.v19.i41.6969 · Cited by 252 · cited 1×
“PNPLA3I148M is associated with increased hepatic fat content, elevated liver enzymes, hepatic fibrosis, and cirrhosis [20,25,26].”
BackgroundHardy, T., Zeybel, M., Day, C. P., Dipper, C., Masson, S., McPherson, S., Henderson, E., Tiniakos, D., White, S., French, J., et al. (2017) · Gut · doi:10.1136/gutjnl-2016-311526 · Cited by 216 · cited 1×
“The same group later detected hypermethylation at the PPARg promoter by analyzing plasma cell-free circulating DNA methylation [102].”
BackgroundCharacterizing DNA methylation alterations from The Cancer Genome Atlas
Weisenberger, D. J. (2014) · Journal of Clinical Investigation · doi:10.1172/jci69740 · Cited by 200 · cited 1×
“Alterations of DNA methylation linked to NAFLD The causal relationship between differential DNA methylation and disease has been extensively studied for various types of cancer [99].”
BackgroundZeybel, M., Hardy, T., Robinson, S. M., Fox, C., Anstee, Q. M., Ness, T., Masson, S., Mathers, J. C., French, J., White, S., et al. (2015) · Clinical Epigenetics · doi:10.1186/s13148-015-0056-6 · Cited by 180
Loss of hepatic Mboat7 leads to liver fibrosis
Thangapandi, V. R., Knittelfelder, O., Brosch, M., Patsenker, E., Vvedenskaya, O., Buch, S., Hinz, S., Hendricks, A., Nati, M., Herrmann, A., et al. (2021) · Gut · doi:10.1136/gutjnl-2020-320853 · Cited by 125
Hoekstra, M., Li, Z., Kruijt, J. K., Eck, M. V., Berkel, T. J. C. V., & Kuiper, J. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2009.11.004 · Cited by 108 · cited 1×
“High carbohydrate levels cause transcriptional upregulation of Pnpla3 and indirect inhibition of protein degradation [33], whereas Pnpla3 expression was reduced in mice by fasting [33,35].”
BackgroundAllen, N. E., Appleby, P. N., Kaaks, R., Rinaldi, S., Davey, G. K., & Key, T. J. (2003) · Cancer Causes & Control · doi:10.1023/a:1022518321634 · Cited by 104 · cited 1×
“Disorders such as reduced plasma levels of IGF-1-binding protein 2 (IGFBP-2), which controls the bioavailability of IGF-1 and contributes to the development of obesity, have been observed in obese adults [105,106].”
BackgroundInsulin-Like Growth Factor Binding Protein 2 (IGFBP-2) and the Risk of Developing Type 2 Diabetes
Wittenbecher, C., Ouni, M., Kuxhaus, O., Jähnert, M., Gottmann, P., Teichmann, A., Meidtner, K., Kriebel, J., Grallert, H., Pischon, T., et al. (2019) · Diabetes · doi:10.2337/db18-0620 · Cited by 76
Self-citationKoyama, S., Horie, T., Nishino, T., Baba, O., Sowa, N., Miyasaka, Y., Kuwabara, Y., Nakao, T., Nishiga, M., Nishi, H., et al. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.119.012609 · Cited by 23
Laeger, T., Castaño-Martinez, T., Werno, M. W., Japtok, L., Baumeier, C., Jonas, W., Kleuser, B., & Schürmann, A. (2018) · Diabetologia · doi:10.1007/s00125-018-4595-1 · Cited by 17 · cited 1×
“To determine whether the hepatic expression and methylation of Dpp4 could be influenced by diet, we used the New Zealand obese (NZO) mouse model, which is known for its early onset of hyperglycemia and T2D that can be postponed by low-protein diets [112].”
MethodSelf-citation
Cited by
Quek, J., Chan, K. E., Wong, Z. Y., Tan, C., Tan, B., Lim, W. H., Tan, D. J. H., Tang, A. S. P., Tay, P., Xiao, J., et al. (2023) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(22)00317-x · Cited by 749
Role of Insulin Resistance in MAFLD
Sakurai, Y., Kubota, N., Yamauchi, T., & Kadowaki, T. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22084156 · Cited by 448
Non-Alcoholic Fatty Liver Disease: Metabolic, Genetic, Epigenetic and Environmental Risk Factors
Juanola, O., Martínez-López, S., Francés, R., & Gómez-Hurtado, I. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18105227 · Cited by 302
Metabolic subtypes of patients with NAFLD exhibit distinctive cardiovascular risk profiles
Martínez‐Arranz, I., Bruzzone, C., Noureddin, M., Gil‐Redondo, R., Mincholé, I., Bizkarguenaga, M., Arretxe, E., Iruarrizaga‐Lejarreta, M., Fernández‐Ramos, D., Lopitz‐Otsoa, F., et al. (2022) · Hepatology · doi:10.1002/hep.32427 · Cited by 65
Bharaj, I. S., Brar, A. S., Kahlon, J., Singh, A., Hotwani, P., Kumar, V., Sohal, A., & Batta, A. (2025) · World Journal of Cardiology · doi:10.4330/wjc.v17.i6.106147 · Cited by 19
Metadata
- Authors
- Jonas, W., & Schürmann, A.
- Venue
- Molecular Metabolism
- Publisher
- Elsevier BV
- Published
- 2021-08
- Volume
- 50
- Pages
- 101111
- ISSN
- 2212-8778 (ISSN-L)
- OpenAlex
- W3095035989
- Cited by
- 157
- References
- 39
- FWCI
- 11.37
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.